Hypertrophic cardiomyopathy refers to an increase in cardiac weight and volume that occurs in response to multiple injurious factors to accommodate an increase in the work done by the heart. Ace Therapeutics aims to provide integrated services for basic research and drug development for hypertrophic cardiomyopathy, so as to further investigate the pathogenesis of hypertrophic cardiomyopathy as well as therapeutic approaches.
Hypertrophic cardiomyopathy is a common inherited primary cardiomyopathy caused mainly by pathogenic mutations in the genes encoding myocardial sarcomere-associated proteins. Hypertrophic cardiomyopathy presents as a progressive damaging lesion of cardiomyocytes and is clinically characterized by thickening of the ventricular wall. It is now generally accepted that most hypertrophic cardiomyopathy is a monogenic disorder, triggered primarily by variants in the genes encoding myocardial sarcomere-associated proteins.
Fig. 1 Therapeutic strategies for obstructive hypertrophic cardiomyopathy. (Braunwald E, et al., 2023)
In 2016, the introduction of Mavacamten, a small molecule inhibitor of myocardial ganglionic contractile proteins, marked the beginning of the development of therapeutic drugs specific for hypertrophic cardiomyopathy. Recently, a growing number of drugs have been developed for different types and targets of hypertrophic cardiomyopathy.
| Drug Name | Drug Target | Original Organization | Drug Phase |
|---|---|---|---|
| Mavacamten | Cardiac myosin | Bristol Myers Squibb Co. | Approved |
| Metoprolol Tartrate | β1-adrenergic receptor | AstraZeneca PLC | Approved |
| Aficamten | Cardiac myosin | Cytokinetics, Inc. | Phase 3 |
| Tc-99m-annexin V-128 | Phosphatidylserine | Advanced Accelerator Applications USA, Inc. | Phase 2 |
| DiNA-001 | MYBPC3 | DiNAQOR AG | Phase 1 |
| TN-201 | MYBPC3 | Tenaya Therapeutics, Inc. | Phase 1 |
Ace Therapeutics is committed to supporting basic research and development of novel therapeutic approaches for hypertrophic cardiomyopathy by providing outsourced research services for disease model development and research technology platforms.
Research Models
Basic Research
Drug Development
A suitable research model is essential for hypertrophic cardiomyopathy research. We are committed to providing diversified development services for animal models of hypertrophic cardiomyopathy to help our clients advance basic research and drug discovery in hypertrophic cardiomyopathy.
Custom Animal Models of Hypertrophic Cardiomyopathy
Based on customers' individual experimental needs, we can build a variety of hypertrophic cardiomyopathy models through different modeling methods, which include surgical narrowing of the aorta, drug or chemical induced hypertrophic cardiomyopathy models.
Transgenic Animal Model Development Services
We are able to provide customized transgenic or knockout animal models to support animal studies on the pathogenic mechanisms of hypertrophic cardiomyopathy, including but not limited to the following genes:
Genetically Engineered Mouse Models
We can provide the following high quality genetically engineered mice for hypertrophic cardiomyopathy.
Cardiomyocytes
For in vitro research, we are able to provide our customers with a wide range of cardiomyocyte cell lines.
We aim to help our clients solve the difficulties encountered in the research of hypertrophic cardiomyopathy, and provide professional research services including novel biomarker development, pathology and imaging tests.
Novel Biomarker Discovery Services
It is important to detect biomarkers in the blood both to predict the development of hypertrophic cardiomyopathy and to aid in its diagnosis. Based on our professional multi-omics research technology platform, we are able to provide customized discovery and identification of novel biomarkers for hypertrophic cardiomyopathy.
Pathology and Imaging Services
For animal research of hypertrophic cardiomyopathy, we can provide researchers with pathology and imaging services that enable intuitive model validation and efficacy assessment, including but not limited to:
We can provide research and development services for hypertrophic cardiomyopathy drug therapies, including but not limited to the following drug types and targets:
R&D Services by Drug Type
R&D Services by Target
Ace Therapeutics has accumulated extensive knowledge in the field of hypertrophic cardiomyopathy, which can provide our customers with basic research, biomarker development, and novel therapies discovery services. If you are interested in our research services for hypertrophic cardiomyopathy, please do not hesitate to contact us.
Ace Therapeutics offers comprehensive solutions and R&D services to researchers worldwide to advance the field of cardiovascular diseases.
We do not provide medical care for patients.
Copyright © Ace Therapeutics. All rights reserved.